<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">Enhanced clinical recovery (from 16.0 to 17.0 days) and reduced fatality (from 19.0% to 27.1%) were detected in an ad hoc subgroup of patients who received treatment within 12 days of symptom onset, but not in patients who received treatment later [
 <xref rid="bib63" ref-type="bibr">63</xref>]. In another study of 280 individuals with COVID-19, the time from onset to antiviral treatment was considered a risk factor for serious illness. Patients in the mild group received antiviral treatment earlier (Severe group 1.19 ± 0.45 days compared with 2.65 ± 1.06 days, p &lt; 0.001) [
 <xref rid="bib62" ref-type="bibr">62</xref>]. Whether early COVID-19 treatment with lopinavir/ritonavir has clinical applications is an important question that required further research.
</p>
